Sanofi (SNY) Research & Development (2009 - 2026)

Sanofi has disclosed Research & Development across 18 years of filings, most recently posting -$2.6 billion for Q2 2026.

• In Q2 2026, Research & Development fell 20.11% year-over-year to -$2.6 billion; the TTM figure through Jun 2026 stood at -$20.3 billion (down 45.3% YoY), while the FY2025 annual figure was $9.1 billion, up 214.07% from the prior year.
• Research & Development came in at -$2.6 billion for Q2 2026 at Sanofi, down from -$2.0 billion in the prior quarter.
• In the past five years, Research & Development ranged from a high of -$1.7 billion in Q1 2022 to a low of -$9.1 billion in Q4 2025.
• Average Research & Development over 5 years is -$3.4 billion, with a median of -$1.9 billion recorded in 2024.
• Year-over-year, Research & Development fell 0.33% in 2023 and slumped 227.92% in 2025.
• Over 5 years, Research & Development stood at -$6.6 billion in 2022, then declined by 5.56% to -$7.0 billion in 2023, then retreated by 12.86% to -$7.9 billion in 2024, then slipped by 15.53% to -$9.1 billion in 2025, then jumped by 71.57% to -$2.6 billion in 2026.
• Per Business Quant data, the three most recent Research & Development figures were -$2.6 billion in Q2 2026, -$2.0 billion in Q1 2026, and -$9.1 billion in Q4 2025.